Table 2

Patients included in the study
Study number Study popul-ation ARR Serum aldosterone (nmol/L) CT 131I-chol-scint AVS Diagnose PAD
1 14 NSP 1.30 0.69 - - - AH
2 1042 NSP 2.50 0.54 + (L) - - AH
3 1052 NSP 3.10 0.46 / / / Normal
4 1065 NSP 4.30 0.64 + (R) - Excluded
5 1092 NSP 1.50 0.75 / / / Normal
6 1105 NSP 2.00 0.62 / / / Normal
7 2002 SP 2.10 0.60 / / / Normal
8 2006 SP 3.80 0.49 - (x2) + (B) + (L) APA (L) NAH
9 2007 SP 4.30 0.64 + (R) - + (R) APA (R) NAH
10 2010 SP 2.90 0.43 -(?L) - + (L?) APA/AH Adenoma
11 2014 SP 4.50 0.68 - - (?R) + (R) APA (R) NAH
12 2022 SP 6.80 1.29 - - - AH
13 2036 SP 2.90 0.43 / / / Normal
14 2037 SP 4.50 0.95 / / / Normal
15 2042 SP 1.70 0.44 - - + (L) APA (L) NAH
16 2049 SP 9.30 1.39 + - Excluded
17 2060 SP 3.30 0.89 + (R) - + (R) APA (R)
18 2069 SP 1.64 0.56 / / / Normal
19 2070 SP 2.40 0.88 + (L) - - AH
20 2074 SP 4.95 0.65 - / / AH
21 2082 SP 3.80 0.50 - / / AH
22 2083 SP 2.10 1.10 + (R) + (R) + (R) APA (R) Adenoma
23 2084 SP 3.90 0.86 - + (L) + (L) APA (L) Adenoma
24 2086 SP 1.40 0.60 + (L) - + (L) APA (L) NAH
25 2099 SP 7.20 1.69 + (L) - + (L) APA (L) Adenoma
26 2100 SP 3.80 0.50 / / / Normal
27 3005 SP 2.10 0.62 - Excluded
28 3006 SP 3.50 0.94 - - failed

Population defines if the patient was screened in a non-selective (NSP) or a selective (SP) hypertensive population. Values for serum aldosterone and the ratio of s-aldosterone/plasma renin activity (ARR) at inclusion and results of the adrenal CT (CT), 131I-norcholesterol-scintigraphy (131I-chol-scint) and adrenal vein sampling (AVS) are given. For the CT, 131I-chol-scint and AVS the following symbols are used +, - , / and failed, for positive, bilateral overproduction of aldosterone, not executed and failed investigation respectively. The letters (L), (R) and (B) indicate left, right and bilateral respectively. In the diagnose column, Normal, AH and APA are used for normal ie no hyperaldosteronism, adrenal hyperplasia and aldosterone producing adenoma respectively. In the PAD column, NAH is used for cortical nodular hyperplasia and adenoma for cortical adenoma.

Sigurjonsdottir et al.

Sigurjonsdottir et al. BMC Endocrine Disorders 2012 12:17   doi:10.1186/1472-6823-12-17

Open Data